Core Viewpoint - Crystal Tech Holdings (02228) has successfully developed and validated two innovative topical active ingredients for hair loss prevention and growth, leveraging its industry-leading AI molecular discovery platform [1] Group 1: Product Development - The two active ingredients, small molecule Remeanagen™ (XTP-118) and peptide AquaKine™ (XTP-016), have shown significant improvements in hair growth and anti-hair loss efficacy, safety, and onset speed compared to existing products [1] - Both molecules have successfully passed the INCI (International Nomenclature of Cosmetic Ingredients) registration in the United States [1] - The combined formulation product, Groland, has received cosmetic registration from the FDA (Food and Drug Administration), marking a significant entry into the consumer health sector [1] Group 2: Strategic Vision - Crystal Tech's new mission statement emphasizes the integration of AI into every new drug and the incorporation of AI molecules into enhancing everyday life [1] - The company aims to tackle major diseases through drug development while also creating consumer-grade molecular products to improve the quality of life for the general public [1]
晶泰控股(02228)：晶泰AI创新研发平台成功开发生发“双子星”新分子 获得关键国际认证